493 related articles for article (PubMed ID: 22890119)
21. Effect of varenicline on smoking cessation through smoking reduction: a randomized clinical trial.
Ebbert JO; Hughes JR; West RJ; Rennard SI; Russ C; McRae TD; Treadow J; Yu CR; Dutro MP; Park PW
JAMA; 2015 Feb; 313(7):687-94. PubMed ID: 25688780
[TBL] [Abstract][Full Text] [Related]
22. Varenicline in the management of smoking cessation: a single technology appraisal.
Hind D; Tappenden P; Peters J; Kenjegalieva K
Health Technol Assess; 2009 Sep; 13 Suppl 2():9-13. PubMed ID: 19804684
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness of varenicline as an aid to smoking cessation: results of an inter-European observational study.
Boudrez H; Gratziou C; Messig M; Metcalfe M
Curr Med Res Opin; 2011 Apr; 27(4):769-75. PubMed ID: 21294601
[TBL] [Abstract][Full Text] [Related]
24. Use of varenicline for 4 weeks before quitting smoking: decrease in ad lib smoking and increase in smoking cessation rates.
Hajek P; McRobbie HJ; Myers KE; Stapleton J; Dhanji AR
Arch Intern Med; 2011 Apr; 171(8):770-7. PubMed ID: 21518946
[TBL] [Abstract][Full Text] [Related]
25. Varenicline for tobacco dependence treatment in recovering alcohol-dependent smokers: an open-label pilot study.
Hays JT; Croghan IT; Schroeder DR; Ebbert JO; Hurt RD
J Subst Abuse Treat; 2011 Jan; 40(1):102-7. PubMed ID: 20947286
[TBL] [Abstract][Full Text] [Related]
26. The efficacy and safety of a nicotine conjugate vaccine (NicVAX®) or placebo co-administered with varenicline (Champix®) for smoking cessation: study protocol of a phase IIb, double blind, randomized, placebo controlled trial.
Hoogsteder PH; Kotz D; van Spiegel PI; Viechtbauer W; Brauer R; Kessler PD; Kalnik MW; Fahim RE; van Schayck OC
BMC Public Health; 2012 Dec; 12():1052. PubMed ID: 23216646
[TBL] [Abstract][Full Text] [Related]
27. Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial.
Evins AE; Cather C; Pratt SA; Pachas GN; Hoeppner SS; Goff DC; Achtyes ED; Ayer D; Schoenfeld DA
JAMA; 2014 Jan; 311(2):145-54. PubMed ID: 24399553
[TBL] [Abstract][Full Text] [Related]
28. A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers.
Tsai ST; Cho HJ; Cheng HS; Kim CH; Hsueh KC; Billing CB; Williams KE
Clin Ther; 2007 Jun; 29(6):1027-39. PubMed ID: 17692719
[TBL] [Abstract][Full Text] [Related]
29. Changes in health-related quality of life with smoking cessation treatment.
Hays JT; Croghan IT; Baker CL; Cappelleri JC; Bushmakin AG
Eur J Public Health; 2012 Apr; 22(2):224-9. PubMed ID: 20884658
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness of varenicline for smoking cessation at 2 urban academic health centers.
Dhelaria RK; Friderici J; Wu K; Gupta E; Khan C; Rothberg MB
Eur J Intern Med; 2012 Jul; 23(5):461-4. PubMed ID: 22726377
[TBL] [Abstract][Full Text] [Related]
31. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial.
Tonstad S; Tønnesen P; Hajek P; Williams KE; Billing CB; Reeves KR;
JAMA; 2006 Jul; 296(1):64-71. PubMed ID: 16820548
[TBL] [Abstract][Full Text] [Related]
32. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.
Gonzales D; Rennard SI; Nides M; Oncken C; Azoulay S; Billing CB; Watsky EJ; Gong J; Williams KE; Reeves KR;
JAMA; 2006 Jul; 296(1):47-55. PubMed ID: 16820546
[TBL] [Abstract][Full Text] [Related]
33. A double-blind placebo-controlled randomized trial of varenicline for smokeless tobacco dependence in India.
Jain R; Jhanjee S; Jain V; Gupta T; Mittal S; Goelz P; Wileyto EP; Schnoll RA
Nicotine Tob Res; 2014 Jan; 16(1):50-7. PubMed ID: 23946326
[TBL] [Abstract][Full Text] [Related]
34. Stopping smokeless tobacco with varenicline: randomised double blind placebo controlled trial.
Fagerström K; Gilljam H; Metcalfe M; Tonstad S; Messig M
BMJ; 2010 Dec; 341():c6549. PubMed ID: 21134997
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers.
Nakamura M; Oshima A; Fujimoto Y; Maruyama N; Ishibashi T; Reeves KR
Clin Ther; 2007 Jun; 29(6):1040-56. PubMed ID: 17692720
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness of varenicline as an aid to smoking cessation in primary care: an observational study.
Andreas S; Chenot JF; Diebold R; Peachey S; Mann K
Eur Addict Res; 2013; 19(1):47-54. PubMed ID: 22987095
[TBL] [Abstract][Full Text] [Related]
37. Smoking cessation efficacy and safety of varenicline, an alpha4beta2 nicotinic receptor partial agonist.
Tonstad S
J Cardiovasc Nurs; 2006; 21(6):433-6. PubMed ID: 17293731
[TBL] [Abstract][Full Text] [Related]
38. Combination treatment with varenicline and bupropion in an adaptive smoking cessation paradigm.
Rose JE; Behm FM
Am J Psychiatry; 2014 Nov; 171(11):1199-205. PubMed ID: 24934962
[TBL] [Abstract][Full Text] [Related]
39. Varenicline versus bupropion XL for smoking cessation in older adolescents: a randomized, double-blind pilot trial.
Gray KM; Carpenter MJ; Lewis AL; Klintworth EM; Upadhyaya HP
Nicotine Tob Res; 2012 Feb; 14(2):234-9. PubMed ID: 21778151
[TBL] [Abstract][Full Text] [Related]
40. Snus as a smoking cessation aid: a randomized placebo-controlled trial.
Fagerstrom K; Rutqvist LE; Hughes JR
Nicotine Tob Res; 2012 Mar; 14(3):306-12. PubMed ID: 21994343
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
